BACKGROUND Cutaneous biopsy sites are often difficult to discern or are frequently misidentified when patients present for the treatment of skin cancers. This frustrating situation can lead to delays in treatment and wrong site surgeries. Current methods aiming to prevent this situation are not perfect.
I n the United States, more than 4.3 million patients undergo treatment of nonmelanoma skin cancer each year. 1 Many patients wait weeks to months from the time of biopsy to the time of treatment by Mohs micrographic surgery or standard excision. During this time, biopsy sites may heal to become imperceptible. 2 In addition, diffuse actinic damage, previous surgical scars, and multiple biopsy sites can make distinguishing the site to be treated more difficult. The inability to correctly identify a patient's biopsy site is a common problem encountered among dermatologic surgeons and is the most frequent reason for medical malpractice lawsuits. 3 Methods currently performed to correctly identify surgical sites include the use of photography, diagrams, measurements to anatomical landmarks, gauze dermabrasion, biopsy site scar visualization, and patient assistance. 2, 4 These methods bring about various challenges. Documentation and diagrams may be unclear. Patients often have difficulty remembering their biopsy sites. Other authors have demonstrated that patients incorrectly identify their own biopsy sites 16% to 30% of the time, and physicians incorrectly identify sites 6% of the time. When patients and physicians tried to identify the site together, they were incorrect in 4% to 12% of cases. 2, 5 Disagreement between a patient and physician regarding the correct surgical site can lead to delay in treatment and increased costs. 6 The use of biopsy site photography has been shown to decrease the number of wrong site surgeries, 2 and its adoption has been encouraged. 2, 5, 7 Yet, preoperative biopsy photographs are often not provided or are of insufficient quality when patients are referred for treatment. 8 Having a system to accurately identify biopsy sites is imperative to prevent wrong site surgery.
Tattoos are regularly used in the fields of surgery and radiation oncology to correctly identify tumor locations. 9,10 However, these marks are permanent, and many patients dislike their appearance and seek future removal. 11 Ultraviolet tattoos, also known as invisible tattoos, are composed of a special ink that is invisible in natural light but fluoresces when exposed to a Wood's lamp, more commonly known as a black light. Chuang and Gilchrest 6 demonstrated the use of an ultraviolet tattoo in a single biopsy site on a young patient with basal cell nevus syndrome. To the authors' knowledge, this is the first prospective cohort study that examines the efficacy and safety of invisible tattoos in dermatologic surgery.
Dermatologists boast a high predictive value in correctly identifying cutaneous malignancies that will likely need further treatment. 12 The purpose of this study was to determine whether the placement of ultraviolet tattoo ink at the time of biopsying, a suspected cutaneous malignancy would facilitate identification of the site at the time of treatment.
Materials and Methods

Patients
In 2014, patients aged 18 years or older undergoing a skin biopsy for a suspected nonmelanoma skin cancer in the authors' outpatient dermatology clinic were invited to participate in this study. Exclusion criteria were a history of immunosuppression, previous biopsy or radiation at the site in question, history of an adverse reaction to tattoo ink, age less than 18 years, and pregnancy. Participants received written information about the study in either English or Spanish, and informed consent was obtained from each patient. The Nova Southeastern Institutional Review Board approved the project proposal.
Technique
Suspected nonmelanoma skin cancer lesions were marked with a surgical pen and photographed before biopsy ( Figure 1A ). Each lesion was cleaned using an alcohol swab and a 1 to 2 mL solution of 1% lidocaine with epinephrine and bicarbonate was injected into the lesion and the surrounding area. A standard shave biopsy with a 15 blade was performed.
After the biopsy, 2 to 3 drops of SkinCandy Blacklight Invisible Ultraviolet Tattoo Ink (SkinCandy Tattoo Supply; Burbank, CA) were placed in a small tattoo ink cup ( Figure 2 ). A sterile tattoo needle was dipped in the ink cup to saturate the tip. The tattoo needle was then gently pierced into the biopsy site to introduce the ink into the superficial dermis. This was repeated 4 times for a total of 5 passes. Confirmation of the tattoo placement was completed using a Wood's lamp. Hemostasis procedures were repeated as needed, and a bandage was applied.
Depending on the biopsy results, patients were asked to return in 4 to 8 weeks for further treatment as needed. Repeat photographs were taken at the time of the subsequent treatment procedure. At each visit, the patient and the investigator attempted to identify the biopsy site with and without the use of a Wood's lamp. Prebiopsy photographs were only used for confirmation after the site was identified. The visibility of the tattoos were graded by one of 3 dermatologists on 3 occasions immediately after application ( Figure 1B ) and again at the follow-up visit both before and after the treatment procedure ( Figure 1C ,D). The grading scale of the level of fluorescence (LOF) was recorded using a grading scale from 1 to 3 (barely to very visible, respectively) using the Wood's lamp. In cases where no further treatments were needed, patients were offered tattoo surgical removal.
U V T A T T O O F A C I L I T A T E S A C C U R A T E I D E N T I F I C A T I O N O F B I O P S Y S I T E S
Results
In all, 31 patients (11 women, 20 men; mean age 74 [range: 53-96 years]) participated in the study. In total, 51 biopsies were performed with one to four biopsies per patient ( Table 1 ). Most of the biopsy sites occurred on extremities, although tattoos were also placed on the lip, ear, temple, and trunk. Immediately after tattoo application, all sites were fully fluorescent under the Wood's lamp (LOF 3).
Of the 51 total biopsies, 48 were nonmelanoma skin cancers including 39 squamous cell carcinomas (SCCs) and 9 basal cell carcinomas. Two biopsy lesions were diagnosed as actinic keratosis and one was nonmalignant, acroangiodermatitis ( Table 1) .
Follow-up visits for treatment occurred 7 to 161 days after tattoo application (mean 49 days). All tattoo sites corresponded with photographs taken at the time of biopsy. Most lesions (84%) demonstrated very visible fluorescence (LOF 3) at followup; those tattoos had been present for an average of 46 days. Four (9%) tattoos had an LOF of 2 at follow-up; those had been present for an average of 49 days. Three (7%) had an LOF of 1 at follow-up; those tattoos had been present for an average of 92 days. In 35% of cases, the patient was unsure of the biopsy site before Wood's lamp illumination. In 7% of cases, physicians could not confidently identify the site without the aid of ultraviolet light illumination. When used in conjunction with Wood's lamp, physicians confidently identified the site in 100% of the cases. None of the tattoos were visible in natural light.
U V T A T T O O F A C I L I T A T E S A C C U R A T E I D E N T I F I C A T I O N O F B I O P S Y S I T E S D E R M A T O L O G I C S U R G E R Y
Most patients were treated with Mohs micrographic surgery or surgical excision. After surgical treatment, none of the patients had visible evidence of residual tattoo. The 2 patients with actinic keratosis returned 3 weeks after tattoo application, at which time both tattoos were visible (LOF 2-3) and treated with liquid nitrogen. At their follow-up visits, neither tattoo was visible. The patient with the nonmalignant acroangiodermatitis chose not to have her tattoo removed and did not return to the clinic.
Two patients (5 SCCs biopsies) were lost to follow-up; they did not respond to attempts to contact them. Another patient with 2 biopsies positive for SCC returned for follow-up but refused treatment and declined surgical tattoo removal. None of the participants have experienced any adverse reactions related to the tattoo to date.
To explore the relationship of different variables with correct identification of the biopsy site, 12 Fisher exact tests were created-6 for the patient and 6 for the physician. The ability to identify the biopsy site before tattoo illumination was assessed using the following variables: age, sex, diagnosis, location on body, and days elapsed from the time of tattoo placement. Results are shown in Table 2 . Younger patients (age #74 years) were more likely to identify their biopsy sites than older patients (p < .05). The physician was less likely to locate the biopsy site if it was located on the patient's arm compared to other sites (p < .05).
Discussion
In cases of suspected nonmelanoma skin cancer, the authors demonstrated a straightforward, accurate, and discrete method of marking biopsy sites with invisible tattoo ink. This method could be altered to involve simultaneous ink inoculation with a punch The small amount of variability in fluorescence levels seen at follow-up may be due to a variety of factors. A negative trend between fluorescence intensity and the length of time the tattoo remained in the skin was observed. Depth of the biopsy and the amount of ink inoculation in the dermis may have varied slightly among patients. Bleeding or the use of hemostatic agents may have also played a role. Importantly, every tattoo was visible at follow-up.
Like previous studies, the results indicate an inability of dermatologists and patients to correctly locate biopsy sites with absolute confidence and accuracy. The authors acknowledge that the number of participants in this study was modest. Despite this limitation, however, the frequency at which the investigators and patients misidentified or could not identify a specific site is consistent with previous reports. Although biopsy site photography can be helpful, as noted above, photographs vary in quality, and they are not always readily available. Based on the results, if a patient had an invisible tattoo marker but not a suitable photograph, the biopsy site would still be easily identifiable. In addition, the use of invisible tattoos to identify biopsy sites may be of increased clinical importance in the older patient population and in biopsy sites located on the extremities. Larger studies with a wider range in subject age and lesion location could confirm this.
Tattoo ink is not Food and Drug Administrationregulated, and some authors have expressed concerns about the safety of ultraviolet tattoos. Specifically, invisible tattoo ink has been reported to cause To explore the relationship with one's ability to identify the biopsy site, 12 Fisher exact tests were created-6 to examine the patient's ability and 6 for the physician. The ability to identify the biopsy site (yes vs no) for both the patient and the physician was assessed for the after variables as a percentage to the total number of biopsies. For example, 6 of 45 biopsies (13%) were not identifiable by female patients.
granulomatous reactions. [13] [14] [15] The authors acknowledge this potential complication; however, the amount of ink applied to the biopsy site during their described procedure is much less than the amount applied in traditional ornamental tattooing. Furthermore, the most tattoos will be removed with treatment of the suspected skin cancer, and if they are not, the biopsy sites will likely be small and easily amenable to excision if desired. None of their 31 patients developed any adverse reactions from the tattoo ink.
In conclusion, the results demonstrate that ultraviolet ink tattoos provide an easy, inexpensive, safe, and accurate method of marking biopsy sites on the skin. This method has the potential to improve patient safety and decrease malpractice costs by reducing the number of wrong site surgeries in dermatology.
